Bristol-Myers Squibb Co [NYSE: BMY] closed the trading session at $59.82.
The stocks have a year to date performance of 16.59 percent and weekly performance of 7.88 percent. The stock has been moved at 32.76 percent over the last six months. The stock has performed 14.60 percent around the most recent 30 days and changed 21.93 percent over the most recent 3-months.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
If compared to the average trading volume of 10.69M shares, BMY reached to a volume of 27638064 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Bristol-Myers Squibb Co [BMY]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BMY shares is $55.32 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BMY stock is a recommendation set at 2.85. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Citigroup have made an estimate for Bristol-Myers Squibb Co shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on October 25, 2024. While these analysts kept the previous recommendation, Bernstein raised their target price to Mkt Perform. The new note on the price target was released on October 17, 2024, representing the official price target for Bristol-Myers Squibb Co stock. Previously, the target price had yet another raise to $41, while Barclays analysts kept a Equal Weight rating on BMY stock.
The Average True Range (ATR) for Bristol-Myers Squibb Co is set at 1.68, with the Price to Sales ratio for BMY stock in the period of the last 12 months amounting to 2.53. The Price to Book ratio for the last quarter was 7.08, with the Price to Cash per share for the same quarter was set at 4.03. Price to Free Cash Flow for BMY in the course of the last twelve months was 8.70 with Quick ratio for the last quarter at 1.09.
BMY stock trade performance evaluation
Bristol-Myers Squibb Co [BMY] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 7.88. With this latest performance, BMY shares gained by 14.60% in over the last four-week period, additionally plugging by 32.76% over the last 6 months – not to mention a rise of 18.67% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BMY stock in for the last two-week period is set at 71.80, with the RSI for the last a single of trading hit 75.18, and the three-weeks RSI is set at 69.37 for Bristol-Myers Squibb Co [BMY]. The present Moving Average for the last 50 days of trading for this stock 52.07, while it was recorded at 55.98 for the last single week of trading, and 48.13 for the last 200 days.
Bristol-Myers Squibb Co [BMY]: An insightful look at the core fundamentals
Bristol-Myers Squibb Co’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.09 and a Current Ratio set at 1.24.
Earnings per share (EPS) analysis for Bristol-Myers Squibb Co [BMY] stock
With the latest financial reports released by the company, Bristol-Myers Squibb Co posted 1.59/share EPS, while the average EPS was predicted by analysts to be reported at 1.43/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.16. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BMY. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Bristol-Myers Squibb Co go to -3.66%.
Bristol-Myers Squibb Co [BMY]: Institutional Ownership
There are presently around $78.13%, or 78.22%% of BMY stock, in the hands of institutional investors. The top three institutional holders of BMY stocks are: VANGUARD GROUP INC with ownership of 186.57 million shares, which is approximately 9.2225%. BLACKROCK INC., holding 158.66 million shares of the stock with an approximate value of $$6.59 billion in BMY stocks shares; and BLACKROCK INC., currently with $$3.8 billion in BMY stock with ownership which is approximately 4.5203%.
